Characterization of the NADPH-dependent metabolism of 17beta-estradiol to multiple metabolites by human liver microsomes and selectively expressed human cytochrome P450 3A4 and 3A5.

We characterized the NADPH-dependent metabolism of 17beta-estradiol (E2) by liver microsomes from 21 male and 12 female human subjects. A large number of radioactive estrogen metabolite peaks were detected following incubations of [3H]E2 with male or female human liver microsomes in the presence of NADPH. The structures of 18 hydroxylated or keto estrogen metabolites formed by these microsomes were identified by gas chromatography/mass spectrometry analysis. 2-Hydroxylation (the formation of 2-OH-E2 and 2-OH-E1) was the dominant metabolic pathway with all human liver microsomes tested. The average ratio of 4-OH-E2 to 2-OH-E2 formation was approximately 1:6. A new monohydroxylated E2 metabolite (chemical structure unidentified) was found to be one of the major metabolites formed by human liver microsomes of both genders. 6beta-OH-E2 and 16beta-OH-E2 were also formed in significant quantities, but products of estrogen 16alpha-hydroxylation (16alpha-OH-E2 + 16alpha-OH-E1) were quantitatively minor metabolites. In addition, many other estrogen metabolites such as 6-keto-E2, 6alpha-OH-E2, 7alpha-OH-E2, 12beta-OH-E2, 15alpha-OH-E2, 15beta-OH-E2, 16beta-OH-E1, and 16-keto-E2 were also formed in relatively small quantities. The overall profiles for the E2 metabolites formed by male and female human liver microsomes were similar, and their average rates were not significantly different. The activity of testosterone 6beta-hydroxylation (a selective probe for CYP3A4/5 activity) strongly correlated with the rate of formation of 2-OH-E2, 4-OH-E2, and several other hydroxyestrogen metabolites by both male and female liver microsomes. The dominant role of hepatic CYP3A4 and CYP3A5 in the formation of these hydroxyestrogen metabolites was further confirmed by incubations of selectively expressed human CYP3A4 or CYP3A5 with [3H]E2 and NADPH.

Strong inhibition of estrone-3-sulfatase activity by pregnenolone 16alpha-carbonitrile but not by several analogs lacking a 16alpha-nitrile group.

In recent years, development of potent inhibitors for estrogen sulfatases has become an actively pursued strategy for chemoprevention and/or chemotherapy of estrogen-dependent human breast cancers. We report here our findings that pregnenolone 16alpha-carbonitrile (PCN) is a potent inhibitor of estrone-3-sulfatase activity of rats and also humans. PCN inhibited in a concentration-dependent manner the desulfation of estrone-3-sulfate catalyzed by liver microsomal and nuclear fractions of female Sprague-Dawley rats. The inhibition of estrone-3-sulfatase activity in these two subcellular fractions showed a biphasic pattern, with a highly sensitive phase seen at 78 nM to 1.25 microm of PCN followed by a markedly less-sensitive phase at > 2.5 microm of PCN. Interestingly, several of PCN's structural analogs without a 16alpha-nitrile group showed little or no inhibitory effect on rat liver microsomal E(1)-3-sulfatase activity. Double-reciprocal analysis showed that the inhibition of rat liver microsomal E(1)-3-sulfatase activity by PCN was essentially competitive in nature. When microsomes from six human term placentas were tested for their E(1)-3-sulfatase activity, PCN showed a similar biphasic inhibition of placental E(1)-3-sulfatase. Likewise, several of its structural analogs showed little or no inhibitory effect on placental E(1)-3-sulfatase activity. Computational analysis of the D-ring structure of PCN and other structurally similar analogs used in the study suggests that the potent sulfatase-inhibiting activity of PCN may be partly due to its unique steric orientation and size of the 16alpha-nitrile group. This knowledge may be useful for the rational design of more potent steroidal inhibitors of E(1)-3-sulfatase by introducing an additional nitrile group to their C16alpha-position.

Selected pharmacodynamic and biochemical properties of selenonium choline.

1. Five minutes after intravenous administration of 50 mg/kg of the novel choline analogue selenonium choline [(CH3)2Se + CH2CH2OH, SeCh], only 8% of the administered dose was accounted for in blood, brain, liver, heart, and kidney tissues. 2. SeCh was acetylated in vivo to acetylselenonium choline (ASeCh) in all of the tissues examined. 3. During postmortem incubation, brain concentrations of SeCh and ASeCh increased to 535% and to 425%, respectively. 4. K(m) and Vmax values for the phosphorylation of SeCh by choline kinase were higher and lower, respectively, compared to the phosphorylation of choline. 5. Acetylation of SeCh was described with K(m) and Vmax values that were both higher than the values for Ch. 6. The data suggest that SeCh is phosphorylated and incorporated into various lipids in brain tissue, and is acetylated to ASeCh by both nonneural and neural tissues.

Modification of the duration of action and pharmacodynamics of arecoline by tetraisopropylpyrophosphoramide.

Tetraisopropylpyrophosphoramide (ISO-OMPA) pretreatment in the mouse was examined for its ability to prolong the time course of arecoline (ARE) concentration using brain ARE concentration as an index. Brain ARE levels were also correlated with acetylcholine (ACh) and choline concentrations. Pretreatment with 40 mg kg-1 ISO-OMPA increased ARE brain concentrations from 3 nmoles g-1 to 76 nmoles g-1 15 min after i.p. administration of 25 mg kg-1 ARE. ARE (25 mg kg-1) alone significantly increased brain ACh and choline levels. In time course studies, administration of ARE (15 mg kg-1) produced a peak brain level of 7.9 nmoles g-1 at 3 min. ISO-OMPA pretreatment increased the peak level of ARE to 46.5 nmoles g-1 and the peak time to 7-15 min. The time of maximum brain elevation of ACh and choline produced by ARE alone lagged slightly behind the peak level time observed for ARE. ARE alone produced a maximal increase in ACh and choline levels to 34.1 and 57.1 nmoles g-1, respectively. In the presence of ISO-OMPA, ARE further increased ACh and choline levels to 48.2 and 103 nmoles g-1, respectively. After i.p. administration the highest concentration of ARE was found in the cortex, followed by the subcortex, and cerebellum. A significant elevation of ACh was observed in the cortex.

Synthesis of novel tellurium containing analogues of choline and acetylcholine and their quantitation by pyrolysis-gas chromatography-mass spectrometry.

Methods for the synthesis and quantitation of the novel choline analogues, telluronium choline and acetyltelluronium choline, are described. An assay procedure utilizing pyrolysis-gas chromatography-mass spectrometry (Py-GC-MS) with cold trapping was developed with [2H4]telluronium choline and [2H4]acetyltelluronium choline as internal standards. The telluronium compounds were ion-pair extracted from tissue with dipicrylamine, washed with 2-butanone, and pyrolyzed prior to GC-MS analysis. The compounds were monitored using selected ion monitoring at m/z 232 and m/z 190 for acetyltelluronium and telluronium choline, respectively, and at m/z 236 and m/z 194 for the analogous deuterated internal standards. The assay was linear over a range of 20 pmol-20 nmol of compound taken through the assay.

Further biological activities of the novel choline analogs selenonium choline and acetylselenonium choline.

The pharmacological actions of the novel choline analog, selenonium choline [(CH3)2Se+CH2CH2OH] and its acetyl ester acetylselenonium choline (ASeCh) were studied in vivo and in vitro. ASeCh produced a dose-related decrease in mean arterial pressure in the rat similar to acetylcholine (ACh) but was 1% to 2% as potent. ASeCh demonstrated agonist activity on the rat isolated ileum and was approximately 2% as active as ACh. Selenonium chlorine (SeCh) was taken up and acetylated in brain tissue slices in a time- and concentration-dependent manner. The use of KCl as a loading stimulus did not increase the uptake of SeCh but increased tissue levels of ASeCh 1.5-fold over the control concentrations. The uptake of SeCh was described by a single low-affinity uptake component (Km = 167 microM) that was not blocked by hemicholinium-3. In contrast, hemicholinium significantly blocked the acetylation of SeCh. Compared with basal release, depolarization with KCl caused a significant release of ASeCh into the incubation medium. A neural specificity was suggested for the in vitro uptake of SeCh. Acetylation of SeCh in vivo in the rat after intraventricular administration was similar to the extent of acetylation of [2H4]-choline. ASeCh bound to both M1 and M2 cholinergic receptors with 2% to 3% of the affinity observed for ACh. These data suggest that SeCh may satisfy criteria for a false neurotransmitter precursor.

Elucidation of the rapid in vivo metabolism of arecoline.

1. The metabolism of arecoline (ARE) was examined in homogenates of mouse blood, brain, kidney, and liver tissue. 2. Liver and kidney tissues exhibited the greatest rates of ARE metabolism. 3. The specific carboxylesterase inhibitor TOCP (tri-o-tolyl-phosphate) as well as ISO-OMPA (tetraisopropyl-pyrophosphoramide) completely blocked ARE metabolism in liver homogenate. 4. ISO-OMPA significantly inhibited ARE metabolism by purified porcine liver carboxylesterase. 5. The data suggest that carboxylesterase (EC 3.1.1.1) is primarily responsible for the metabolism of ARE in the mouse.

Synthesis and cholinergic properties of N-aryl-2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethylamino analogs of ranitidine.

A series of N-aryl-2-[[[5-[(dimethylamino)methyl]-2- furanyl]methyl]thio]ethylamino analogs of the H2-antagonist, ranitidine, was synthesized and the abilities of the compounds to alleviate the cholinergic deficit characteristic of Alzheimer's disease evaluated. The compounds were initially tested for their ability to inhibit human erythrocyte acetylcholinesterase activity in vitro. Selected compounds were further evaluated for butyrylcholinesterase inhibition, M1 and M2 cholinergic receptor binding, potentiation of ileal contractions, and the ability to elevate brain acetylcholine levels in mice. The analogs were compared to tetrahydroaminoacridine and to a recently reported series of bis-[[(dimethylamino)methyl]furans]. The N-aryl-2-[[[5-[(dimethylamino)methyl]-2- furanyl]methyl]thio]ethylamine derivatives were generally comparable to tetrahydroaminoacridine and the bis[[(dimethylamino)methyl]furans] in acetylcholinesterase inhibition, M1/M2 receptor binding, and the potentiation of ileal contractions, while being more potent inhibitors of acetylcholinesterase than butyrylcholinesterase. The 4-nitro-3-pyridazinyl analog, 26, was notable in demonstrating a potent and selective binding to the M2 receptor, with an M2 IC50/M1 IC50 of 0.060. Compounds in which the substituents on the dinitro-N-aryl moiety were relatively small were the best at inhibiting acetylcholinesterase in vitro. The N-aryl-2-[[[5-[(dimethylamino)methyl]-2- furanyl]methyl]thio]ethylamines in general, and those with small N-aryl substituents in particular, were superior to the bis[[(dimethylamino)methyl]furans] in elevating brain ACh levels in mice, probably due to enhanced distribution into the CNS. The 1,5-difluoro-2,4-dinitrophenyl analog, 8, resulted in the largest elevation in brain acetylcholine levels, affording a 53% increase at 88 mg/kg.

Selected biological activities of novel selenonium choline analogs.

1. The novel choline analogs selenonium choline (SeCh) and acetylselenonium choline (ASeCh) have been examined for selected biological activities. 2. ASeCh was found to be an alternative substrate for acetylcholine esterase with Km and Vmax values similar to acetylcholine. 3. ASeCh and SeCh inhibited acetylthiocholine hydrolysis by acetylcholinesterase with IC50 values similar to acetylcholine and choline. 4. SeCh exerted a protective action against physostigmine and DFP induced toxicity. 5. SeCh (85 mg/kg) was found to be 3 times more toxic in mice than choline.

Simultaneous quantitation of arecoline, acetylcholine, and choline in tissue using gas chromatography/electron impact mass spectrometry.

A capillary gas chromatography/mass spectrometry (GC/MS) assay for the simultaneous quantitation of arecoline (ARE), acetylcholine (ACh), and choline (Ch) in biological tissue has been developed. The method utilizes hexadeuterated ARE and nonadeuterated ACh and Ch as internal standards. The compounds were ion-pair extracted from tissue using sodium tetraphenylboron in 3-heptanone. GC/MS analysis was achieved using capillary GC and electron impact mass spectrometry. Quantitation was accomplished using selected ion monitoring at m/z 140 and 146 for non-deuterated and deuterated arecoline respectively, and m/z 58 and 64 for non-deuterated and deuterated ACh and Ch respectively. The method easily detected 25 pmol of all three compounds taken through the assay, and was linear through 50 nmol.

Synthesis and cholinergic properties of bis[[(dimethylamino)methyl]furanyl] analogues of ranitidine.

The histaminergic H2 antagonist, ranitidine, has also been found to significantly inhibit acetylcholinesterase (AChE) in vitro. In an effort to develop novel, nonquaternary AChE inhibitors capable of penetrating into the CNS and alleviating the cholinergic deficit characteristic of Alzheimer's disease, a series of bis[[(dimethylamino)methyl]furanyl] analogues of ranitidine has been synthesized. All compounds were evaluated for human erythrocyte AChE inhibitory activity and compared to ranitidine, physostigmine, and tetrahydro-9-aminoacridine (THA). The most active AChE inhibitors were N,N'-disubstituted derivatives of 2-nitro-1,1-ethenediamine and 4,6-dinitro-1,3-benzenediamine, with compound 8 demonstrating activity greater than physostigmine. Deletion of the diaminonitroethene group in a series of alkyl and aryl bis-thioethers, yielded a number of slightly less active compounds, comparable in potency to THA. The 13 most active AChE inhibitors all demonstrated a more selective inhibition of AChE, as opposed to butyrylcholinesterase inhibition, than did THA. Compounds 3 and 22 were equally active to THA in potentiating rat ileal contractions. Binding studies demonstrated M1 and M2 cholinergic receptor affinities slightly greater than or equal to THA. Differential receptor binding studies showed compound 12 resembled THA in agonist/antagonist activity. Compounds 11-13 significantly elevated mouse brain acetylcholine levels, when administered at 80% of their approximate lethal doses, but were less active than THA or physostigmine.

Muscarinic and nicotinic activities of the novel acetylcholine analog acetylselenonium choline.

The present paper further characterizes the cholinergic properties of acetylselenonium choline (ASeCh, (CH3)2Se+CH2CH2OCOCH3). The data demonstrate that ASeCh possesses muscarinic receptor agonist properties as evidenced by vasodepressor and smooth muscle contractile activities which are enhanced by physostigmine and antagonized by atropine. ASeCh also possessed nicotinic agonist activity on frog rectus abdominis tissue which was potentiated by physostigmine, and blocked by d-tubocurarine. The relative potencies of ASeCh ranged from approximately 1% to approximately 6% of the potency of acetylcholine in the three types of preparations examined.

A comparison of the cholinergic activity of selected H2-antagonists and sulfoxide metabolites.

Famotidine and selected H2-antagonists were evaluated with respect to toxicity and selected pharmacological activities. When administered intraperitoneally to mice at a dose equivalent to 10 times their respective H2-antagonist ED50 values, no deaths were observed. Similarly, no alteration in brain ACh concentrations or overt pharmacological effects were noted. However, at 400 mg/kg, ranitidine produced 89% lethality, followed by cimetidine (11%) and famotidine. Only cimetidine and famotidine at this dose significantly elevated brain acetylcholine levels. These results do not correlate with the in vitro data, where ORF-17578 and ranitidine were the most potent entities with respect to acetylcholinesterase inhibition (approximately 1-2 X 10(-6) M), followed by nizatidine greater than cimetidine greater than famotidine. The sulfoxide metabolites of ranitidine and cimetidine were approximately one-tenth as potent as their parent compounds with respect to inhibition of acetylcholinesterase. Direct muscarinic stimulation or potentiation of acetylcholine-induced contraction in ileal tissue was not observed for any of the H2-antagonists.

Prevention of physostigmine-, DFP-, and diazinon-induced acute toxicity by monoethylcholine and N-aminodeanol.

1. Choline, and the choline analogues monoethylcholine (MEC) and N-aminodeanol (NAD) were examined for prophylactic activity in acute acetylcholinesterase inhibitor toxicity in mice. The rank order of potency of the compounds was MEC greater than NAD greater than choline. 2. Simultaneous administration of MEC (60 mg kg-1) or NAD (200 mg kg-1) with physostigmine reduced lethality to 17 and 13% respectively. MEC (60 mg kg-1) completely protected against disopropylfluorophosphate (DFP) and diazinon toxicity, and NAD reduced lethality to 17% for both agents. Choline (200 mg kg-1) exhibited only negligible antidotal activity against the inhibitors. 3. In vitro concentrations of choline, MEC, and NAD, similar to the estimated concentration obtained in vivo in the acute toxicity study, produced mixed inhibition of mouse brain acetylcholinesterase. The inhibition was dose-related and was additive to the inhibition produced by the cholinesterase inhibitors. 4. All three analogues reduced ligand binding at the nicotinic, M1, and M2 receptors. The rank order of potencies for the analogues at each receptor was nicotinic: (choline greater than MEC greater than NAD), M1: (MEC greater than choline greater than NAD), and M2: (MEC greater than choline greater than NAD). 5. It is proposed that the analogues prevent acetylcholinesterase inhibitor toxicity peripherally by interacting with acetylcholinesterase, and/or by competing with acetylcholine for binding to cholinoceptors.

Antagonism of acute physostigmine and neostigmine toxicity in mice by hemicholinium-3.

Hemicholinium-3 (HC-3) was administered intraperitoneally to mice concurrently with the intraperitoneal administration of physostigmine or neostigmine. HC-3 increased the LD50 values for both physostigmine and neostigmine but did not alter the effect on brain ACh levels produced by these agents. Since HC-3 does not cross the blood brain barrier after intraperitoneal administration, the antidoting action of HC-3 is peripherally mediated and does not solely involve an inhibition of ACh synthesis. The increase in brain acetylcholine caused by neostigmine was related to a reduction in acetylcholinesterase activity, providing evidence that intraperitoneally administered neostigmine crosses the blood-brain barrier.

The effect of hemicholinium-3 and physostigmine on choline in rat brain.

Physostigmine and hemicholinium-3 were examined for their effects on rat brain choline levels after microwave irradiation and after postmortem incubation. Hemicholinium-3 and physostigmine increased choline levels in the cerebellum and striatum when measured after microwave irradiation, but decreased the level of choline produced after postmortem incubation of the brain areas. Addition of the drugs in vitro to whole brain homogenates also decreased postmortem choline production. The data shows that the effect of hemicholinium-3 and physostigmine on in vivo choline levels can be differentiated from their effects on the postmortem production of choline, suggesting that the drugs are affecting at least two of the regulatory processes for choline in the brain.

Is propionylcholine present in or synthesized by electric organ?

When small blocks comprising four columns of electrocytes were excised from electric organs of Torpedo marmorata after stimulation in vivo via the electric lobe at 1 Hz for 1 h and allowed to recover at 20-22 degrees C for several hours in medium containing 100 microM d4 choline and 500 microM propionate, small quantities of propionylcholine amounting to no more than 1% of the endogenous acetylcholine of the tissue could be detected in tissue extracts by gas chromatography-mass spectrometry (GCMS). Kinetic studies demonstrated that there was no nonexchangeable propionylcholine in the tissue and in the absence of added propionate, propionylcholine levels were less than 0.2% of tissue acetylcholine. Vesicular propionylcholine amounted to less than 0.5% of vesicular acetylcholine and the distribution of d0 and d4 propionylcholine suggested that an appreciable proportion (up to one-third) of this could be an artifact of preparation for GCMS determinations. Propionylcholine formation during extraction and demethylation of an artificial mixture of acetylcholine, choline, and propionate was indeed detected. It is concluded that propionylcholine has no significance as an endogenous or as a false transmitter at this terminal, in conformity with the work of Sheridan et al. [Z. Zellforsch. 74, 281-307 (1966)] but in contrast to the report of O'Regan [J. Neurochem. 39, 764-772 (1982)].

In vivo acetylation of homocholine and beta-methylcholine in rat brain.

A nitrogen phosphorus-gas chromatographic procedure was modified to determine the extent of in vivo acetylation of the choline analogs homocholine and beta-methylcholine. Infusion of homocholine (18 mumoles) for 2 hours into the lateral ventricle of the rat produced 2.3 nmoles/gram of acetylhomocholine which represented 0.035% of the detected homocholine. Infusion of the same quantity of beta-methylcholine produced 1.0 nmole/gram of acetyl-beta-methylcholine representing 0.025% of the detected beta-methylcholine. Although pretreatment with hemicholinium-3 reduced the amount of acetylated product formed from either analog, the reduction was significant only for acetyl-beta-methylcholine (p less than 0.01).

Separation of recycling and reserve synaptic vesicles from cholinergic nerve terminals of the myenteric plexus of guinea pig ileum.

Acetylcholine-rich synaptic vesicles were isolated from myenteric plexus-longitudinal muscle strips derived from the guinea pig ileum by the method of Dowe, Kilbinger, and Whittaker [J. Neurochem. 35, 993-1003 (1980)] using either unstimulated preparations or preparations field-stimulated at 1 Hz for 10 min using pulses of 1 ms duration and 10 V . cm-1 intensity. The organ bath contained either tetradeuterated (d4) choline (50 microM) or [3H]acetate (2 muCi . ml-1); d4 acetylcholine was measured by gas chromatography-mass spectrometry. As with Torpedo electromotor cholinergic vesicle preparations made under similar conditions the distribution of newly synthesized (d4 or [3H]) acetylcholine in the zonal gradient from stimulated preparations was not identical with that of endogenous (d0, [1H]) acetylcholine, but corresponded to a subpopulation of denser vesicles (equivalent to the VP2 fraction from Torpedo) that had preferentially taken up newly synthesized transmitter. The density difference between the reserve (VP1) and recycling (VP2) vesicles was less than that observed in Torpedo but this smaller difference can be accounted for theoretically by the difference in size between the vesicles of the two tissues. At rest, a lesser incorporation of labelled acetylcholine into the vesicle fraction was observed, and the peaks of endogenous and newly synthesized acetylcholine coincided. Stimulation in the absence of label followed by addition of label did not lead to incorporation of labelled acetylcholine, suggesting that the synthesis and storage of acetylcholine in this preparation and its recovery from stimulation is much more rapid than in Torpedo.